Igm Biosciences
Biotechnology, 325 E Middlefield Rd, Mountain View, California, 94043, United States, 201-500 Employees
Phone Number: 65********
Who is IGM BIOSCIENCES
IGM Biosciences (Nasdaq: IGMS) is a clinical-stage biotechnology company pioneering the development of engineered IgM antibodies for the treatment of cancer, infectious diseases, and auto...
Read More
-
Headquarters: 325 E Middlefield Rd, Mountain View, California, 94043, United States
-
Date Founded: 2010
-
Employees: 201-500
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
-
CEO:
Fred Schwarzer
Email
Phone
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from IGM BIOSCIENCES
IGM Biosciences Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding IGM Biosciences
Answer: IGM Biosciences's headquarters are located at 325 E Middlefield Rd, Mountain View, California, 94043, United States
Answer: IGM Biosciences's phone number is 65********
Answer: IGM Biosciences's official website is https://igmbio.com
Answer: IGM Biosciences's revenue is $10 Million to $25 Million
Answer: IGM Biosciences's SIC: 2834
Answer: IGM Biosciences's NAICS: 325412
Answer: IGM Biosciences has 201-500 employees
Answer: IGM Biosciences is in Biotechnology
Answer: IGM Biosciences contact info: Phone number: 65******** Website: https://igmbio.com
Answer: IGM Biosciences (Nasdaq: IGMS) is a clinical-stage biotechnology company pioneering the development of engineered IgM antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. IgM antibodies have inherent properties that we believe may enable them to bind more strongly to targets on the surface of cells than comparable IgG antibodies. We believe our proprietary IgM antibody technology platform is particularly well suited for developing T cell engagers, receptor cross-linking agonists, targeted cytokines, and target neutralizers. Our lead product candidate, Imvotamab, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins, and it is currently in two Phase 2 clinical trials for the treatment of relapsed and/or refractory diffuse large B cell lymphoma and follicular lymphoma. Our second product candidate is IGM-8444, an IgM antibody targeting Death Receptor 5 (DR5) for the treatment of patients with relapsed and/or refractory solid and hematologic malignancies, and it is currently in a Phase 1 clinical trial. Also in our product pipeline is IGM-7354 and IGM-2644. IGM-7354 is an anti-PD-L1 IgM antibody that targets the delivery of interleukin-15 (IL-15) cytokines to the area of PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month